Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index; 26 of the 48 sources its claims cite were checked for support.
Abstract
BACKGROUND: Ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen (BCMA)-directed CAR T-cell therapy, is effective in heavily pretreated patients with relapsed or refractory multiple myeloma. We investigated cilta-cel in earlier treatment lines in patients with lenalidomide-refractory disease. METHODS: In this phase 3, randomized, open-label trial, we assigned patients with lenalidomide-refractory multiple myeloma to receive cilta-cel or the physician's choice of effective standard care. All the patients had received one to three previous lines of treatment. The primary outcome was progression-free survival. RESULTS: A total of 419 patients underwent randomization (208 to receive cilta-cel and 211 to receive standard care). At a median follow-up of 15.9 months (range, 0.1 to 27.3), the median progression-free survival was not reached in the cilta-cel group and was 11.8 months in the standard-care group (hazard ratio, 0.26; 95% confidence interval [CI], 0.18 to 0.38; P<0.001). Progression-free survival at 12 months was 75.9% (95% CI, 69.4 to 81.1) in the cilta-cel group and 48.6% (95% CI, 41.5 to 55.3) in the standard-care group. More patients in the cilta-cel group than in the standard-care group had an overall response (84.6% vs. 67.3%), a complete response or better (73.1% vs. 21.8%), and an absence of minimal residual disease (60.6% vs. 15.6%). Death from any cause was reported in 39 patients and 46 patients, respectively (hazard ratio, 0.78; 95% CI, 0.5 to 1.2). Most patients reported grade 3 or 4 adverse events during treatment. Among the 176 patients who received cilta-cel in the as-treated population, 134 (76.1%) had cytokine release syndrome (grade 3 or 4, 1.1%; no grade 5), 8 (4.5%) had immune effector cell-associated neurotoxicity syndrome (all grade 1 or 2), 1 had movement and neurocognitive symptoms (grade 1), 16 (9.1%) had cranial nerve palsy (grade 2, 8.0%; grade 3, 1.1%), and 5 (2.8%) had CAR-T-related peripheral neuropathy (grade 1 or 2, 2.3%; grade 3, 0.6%). CONCLUSIONS: A single cilta-cel infusion resulted in a lower risk of disease progression or death than standard care in lenalidomide-refractory patients with multiple myeloma who had received one to three previous therapies. (Funded by Janssen and Legend Biotech; CARTITUDE-4 ClinicalTrials.gov number, NCT04181827.).
Overview
CoChat Summary
TL;DR
In CARTITUDE-4, a single cilta-cel infusion significantly improved progression-free survival versus physician’s choice standard care in lenalidomide-refractory multiple myeloma after one to three prior lines. Cilta-cel also produced higher response and MRD-negativity rates, with mostly manageable CAR-T-specific adverse events.
Key findings
- At a median follow-up of 15.9 months, median progression-free survival was not reached with cilta-cel versus 11.8 months with standard care (HR, 0.26; 95% CI, 0.18 to 0.38; P<0.001); 12-month progression-free survival was 75.9% vs. 48.6%.
- Cilta-cel produced higher overall response (84.6% vs. 67.3%), complete response or better (73.1% vs. 21.8%), and MRD negativity (60.6% vs. 15.6%).
- Overall survival was immature: death from any cause occurred in 39 cilta-cel patients and 46 standard-care patients (HR, 0.78; 95% CI, 0.5 to 1.2; P=0.26); 12-month survival was 84.1% vs. 83.6%.
- Grade 3 or 4 adverse events occurred in 96.6% vs. 94.2%; among 176 as-treated cilta-cel patients, cytokine release syndrome occurred in 76.1% (grade 3 or 4, 1.1%; no grade 5), ICANS in 4.5% (all grade 1 or 2), cranial nerve palsy in 9.1%, and CAR-T-related peripheral neuropathy in 2.8%.
Methods
- Phase 3, randomized, open-label trial at 81 sites in the United States, Europe, Asia, and Australia; 419 patients with lenalidomide-refractory multiple myeloma after one to three prior lines, ECOG performance-status score ≤1, and no prior CAR-T or BCMA-targeted therapy were assigned 1:1 to cilta-cel (208) or standard care (211; PVd or DPd).
- Cilta-cel patients received apheresis, bridging therapy, lymphodepletion, and a single cilta-cel infusion (target dose, 0.75×10^6 CAR+ viable T cells/kg); standard-care patients received DPd or PVd until progression, with no protocol-permitted crossover.
- Primary outcome was progression-free survival; efficacy was analyzed in the intention-to-treat population with Kaplan-Meier estimates, a stratified weighted log-rank test, and stratified Cox regression; adverse events were evaluated in the safety population and CAR-T-specific events in the as-treated population.
Limitations
- Stated: two highly efficacious triplet regimens—daratumumab, carfilzomib, and dexamethasone and isatuximab, carfilzomib, and dexamethasone—were not approved at trial initiation and could not be included as standard-care options.
- Stated: early progression or death during weeks 0 to 8 was higher in the cilta-cel group and all occurred before cilta-cel infusion; this may have been due to lower bridging doses of DPd/PVd, and the benefit did not become apparent until 3 months. Overall survival data were immature.
- Evident: the trial was open-label, the sponsor was involved in data collection, analysis, and interpretation, and median follow-up was 15.9 months, limiting assessment of overall survival; crossover from standard care to cilta-cel was not permitted.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
17 Valid · 2 Not valid · 4 Not checked · 86 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“In the phase 1b-2 CARTITUDE-1 trial involving patients who had received at least three lines of therapy, the median progressionfree survival was 34.9 months. 10-12”
What the sources say
- Not checked — no full text of the sourcecites [10] 10. Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet 2021; 398: 314-24. source
- Disputedcites [11] 11. Martin T, Usmani SZ, Berdeja JG, et al. Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol 2023; 41: 1265-74. sourceExperimental — accuracy not yet measured
The Results > Efficacy section states that median progression-free survival was not reached at a median follow-up of 27.7 months, contrary to the claimed 34.9 months. The Methods > Study Design and Treatment section confirms that CARTITUDE-1 was a phase Ib/II trial, but its eligibility criteria also allowed some patients with fewer than three prior lines of therapy. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
- Not checked — no full text of the sourcecites [12] 12. Lin Y, Martin TG, Usmani SZ, et al. CARTITUDE-1 final results: phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/ refractory multiple myeloma. J Clin Oncol 2023; 41: Suppl: 8009. abstract. source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“High treatment attrition - only 13 to 35% of patients receive four or more lines of therapy - also highlights the need to use effective therapies early. 9”
What the sources say
- Supportedcites [9] 9. Fonseca R, Usmani SZ, Mehra M, et al. Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma. BMC Cancer 2020; 20: 1087. source
Table 4 (Results, Attrition by LOT) shows that 2,971 of 22,062 non-transplant patients (13.5%) and 954 of 2,763 transplant patients (34.5%) received a fourth line of therapy. The Conclusion links high attrition to the need for effective treatment early. These percentages concern patients in the study who received at least one line of therapy, not all patients diagnosed with multiple myeloma. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The frequency of lenalidomide resistance early in the treatment journey is increasing, 1,8”
What the sources say
- Supportedcites [1] 1. van de Donk NWCJ. Sequencing multiple myeloma therapies with and after antibody therapies. Hematology Am Soc Hematol Educ Program 2020; 2020: 248-58. source
In the Introduction sections “Changes in frontline treatment” and “Refractory to lenalidomide,” the paper says that increasing frontline use of lenalidomide is leading to an increasing fraction of patients with lenalidomide-refractory disease at first relapse. This supports the claim about resistance occurring more frequently early in the treatment journey. (LLM, conf=0.94)
- Supportedcites [8] 8. de Arriba de la Fuente F, Montes Gaisán C, de la Rubia Comos J. How to manage patients with lenalidomide-refractory multiple myeloma. Cancers (Basel) 2022; 15: 155. source
The Introduction states that, with extensive use of frontline lenalidomide-based therapies, lenalidomide refractoriness early in the disease course is increasingly common. This directly supports the citing sentence’s paraphrase. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The incidence of movement and neurocognitive adverse events was also lower in CARTITUDE-4 (0.6%) than in CARTITUDE-1 (6.0%)”
What the sources say
- Not checked — no full text of the sourcecites [10] 10. Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet 2021; 398: 314-24. source
- Partly supportedcites [11] 11. Martin T, Usmani SZ, Berdeja JG, et al. Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol 2023; 41: 1265-74. sourceExperimental — accuracy not yet measured
The Results section identifies parkinsonism as previously termed movement and neurocognitive adverse events, and the Discussion reports a 6% incidence in CARTITUDE-1. The paper does not give a CARTITUDE-4 incidence of 0.6%; it instead reports less than 0.5% across other cilta-cel studies without identifying CARTITUDE-4. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“which suggests that cilta-cel may have a better side-effect profile when used earlier in treatment. 10,11”
What the sources say
- Not checked — no full text of the sourcecites [10] 10. Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet 2021; 398: 314-24. source
- Partly supportedcites [11] 11. Martin T, Usmani SZ, Berdeja JG, et al. Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol 2023; 41: 1265-74. sourceExperimental — accuracy not yet measured
The Discussion (page not available) says earlier use of cilta-cel may improve long-term outcomes and notes that prior treatments in this heavily pretreated group are associated with an increased risk of secondary primary malignancies. It does not say that cilta-cel itself would have fewer side effects if used earlier, so the specific safety comparison remains unsupported. (LLM, conf=0.78)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
43 more claims
Create a free account to see all 109 claims and every source verdict.
- Probably not a substantial claim. 35
- It may state two separate claims as one. 30
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The proportion of patients over age 75 years or with an Eastern Cooperative Oncology Group performance status score of 2 were also small but consistent with results reported in studies of similar populations;5,26,28,33 a progression-free survival benefit was still observed with Tec-Dara in these subgroups.”
From Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma (2026) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Patients in the cilta-cel arm of CARTITUDE-4 who had increased tumor burden after bridging therapy or lymphodepletion were assessed as having PD and could receive cilta-cel as subsequent therapy at the investigator ' s discretion 14 ; in KarMMa-3, these patients were permitted to remain on study.”
From Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses. (2024) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Notably in KarMMa-3, 54% (207/386) of patients were enrolled in the United States compared with 15% (64/419) in CARTITUDE-4. 14”
From Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses. (2024) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Ciltacabtagene autoleucel, a BCMA autologous CAR-T therapy, has significantly improved progression-free and overall survival versus DPd/PVd, with an improving adverse event profile from late to earlier lines of treatment.5,25”
From Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma (2026) · cites this paper as [5]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Both ide-cel and cilta-cel have subsequently shown superiority over standard relapsed myeloma regimens in randomized trials conducted earlier in the disease course (Table 9).159,160”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [160]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“During treatment, infections occurred in 129 patients (62.0%) in the cilta-cel group and in 148 (71.2%) in the standard-care group; of these infections, 26.9% and 24.5%, respectively, were of grade 3 or 4.”
Reported 26.9 · recomputed 43.410853
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“| Immune effector cell-associated neuro- toxicity syndrome and associated symptoms | 8/176 (4.5) | 1/176 (0.1)”
Reported 0.1 · recomputed 0.568182
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“MRD negativity at any time during the trial occurred in 60.6% of the patients in the cilta-cel group and in 15.6% of those in the standard-care group, for a risk ratio of 2.2”
Reported 2.2 · recomputed 3.884615
Citations
Cites
Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.12.758 · Cited by 3,675
Berdeja, J. G., Madduri, D., Usmani, S. Z., Jakubowiak, A., Agha, M., Cohen, A. D., Stewart, A. K., Hari, P., Htut, M., Lesokhin, A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00933-8 · Cited by 1,756
Self-citationDaratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Palumbo, A., Chanan-Khan, A., Weisel, K., Nooka, A. K., Masszi, T., Beksac, M., Spicka, I., Hungria, V., Munder, M., Mateos, M. V., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606038 · Cited by 1,522
Self-citationRajkumar, S. V., Harousseau, J.-L., Durie, B., Anderson, K. C., Dimopoulos, M., Kyle, R., Blade, J., Richardson, P., Orlowski, R., Siegel, D., et al. (2011) · Blood · doi:10.1182/blood-2010-10-299487 · Cited by 1,036
Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
Dimopoulos, M. A., Moreau, P., Terpos, E., Mateos, M. V., Zweegman, S., Cook, G., Delforge, M., Hájek, R., Schjesvold, F., Cavo, M., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.014 · Cited by 900
Self-citationIde-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
Rodriguez-Otero, P., Ailawadhi, S., Arnulf, B., Patel, K., Cavo, M., Nooka, A. K., Manier, S., Callander, N., Costa, L. J., Vij, R., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2213614 · Cited by 781
Self-citationMartin, T., Usmani, S. Z., Berdeja, J. G., Agha, M., Cohen, A. D., Hari, P., Avigan, D., Deol, A., Htut, M., Lesokhin, A., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.00842 · Cited by 663
Self-citationDimopoulos, M., Quach, H., Mateos, M.-V., Landgren, O., Leleu, X., Siegel, D., Weisel, K., Yang, H., Klippel, Z., Zahlten-Kumeli, A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30734-0 · Cited by 430
Self-citationMoreau, P., Dimopoulos, M.-A., Mikhael, J., Yong, K., Capra, M., Facon, T., Hajek, R., Špička, I., Baker, R., Kim, K., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00592-4 · Cited by 392
Self-citationRichardson, P. G., Oriol, A., Beksac, M., Liberati, A. M., Galli, M., Schjesvold, F., Lindsay, J., Weisel, K., White, D., Facon, T., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30152-4 · Cited by 386
Self-citation
Cited by
Items 601–700 of 814
High-Risk Myeloma: Definitions and Treatments
Sharma, R., Sanchez-Hernandez, K. A., & Lancman, G. (2024) · Canadian Hematology Today · doi:10.58931/cht.2024.3254
Chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma: The evolving Canadian landscape
Bhella, S. (2023) · Canadian Hematology Today · doi:10.58931/cht.2023.2342
Bal, S., Magnusson, T., Ravi, G., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-5015478/v1
Self-citationCHIMERIC ANTIGEN RECEPTOR T CELLS FOR THE TREATMENT OF MULTIPLE MYELOMA
Testa, U., Pelosi, E., & Castelli, G. (2024) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2024.077
Besemer, B., & Schenk, A. (2024) · TumorDiagnostik & Therapie · doi:10.1055/a-2307-3343
Tix, T., Subklewe, M., von Bergwelt‐Baildon, M., & Rejeski, K. (2024) · Oncology Research and Treatment · doi:10.1159/000542631 · Cited by 6
Expert Opinion on Multiple Myeloma Treatment in Brazil in the Bispecific Antibody Era
Hungria, V., Neto, J. V. P., Garibaldi, P. M. M., Jansen, A. M., Filho, R. J. P. D. M., Pericole, F. V., Sanku, G., & Maiolino, Â. (2024) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2024.12.001 · Cited by 1
Multiple myeloma in Latin America: Are we moving at the same pace as other regions?
Jimenez-Zepeda, V. H. (2023) · Revista Colombiana de Cancerología · doi:10.35509/01239015.986
Visram, A., & Mian, H. S. (2025) · The Lancet Haematology · doi:10.1016/s2352-3026(24)00346-6
Immuntherapien des multiplen Myeloms
Kadel, S., & Rasche, L. (2025) · Die Onkologie · doi:10.1007/s00761-024-01658-0
Myélome multiple : stratégies et objectifs de traitement
Bobin, A., Leleu, X., & Perrot, A. (2024) · EMC - Hématologie · doi:10.1016/s1155-1984(24)47567-5
Phua, C. W. T., & McCulloch, S. (2025) · Canadian Hematology Today · doi:10.58931/cht.2025.4s0161
Long, J., Xie, S., Zhang, W., et al. (2025) · Haematologica · doi:10.3324/haematol.2024.286689
Multiple myeloma and anti-BCMA CAR-T therapy: a literature review
Faenko, A. P., Dudina, G. A., & Mabudzade, C. K. (2025) · MD-Onco · doi:10.17650/2782-3202-2024-4-4-53-64
Therapie des multiplen Myeloms – was ist neu und was bleibt?
Kortüm, K. M., Waldschmidt, J. M., & Einsele, H. (2025) · Die Onkologie · doi:10.1007/s00761-024-01675-z
Self-citationOptimizing Transitions of Care in Multiple Myeloma Immunotherapy: Nurse Roles
Bellerive, C., Steinbach, M., McNeill, A., Faiman, B., & Richards, T. (2025) · Clinical journal of oncology nursing · doi:10.1188/25.cjon.e7e16 · Cited by 4
Radhi, M., Yusuf, D. A., AlSaffar, G. M., & Toorani, Z. A. (2025) · Cureus · doi:10.7759/cureus.80068 · Cited by 1
“These act as a bridging therapy to prepare the body to receive CAR-T, since it is associated with several side effects, which will be addressed in the following sections [39-41].”
InfluentialCurrent and Future Approaches for the Treatment of Plasma Cell Leukemia
Fortuna, G. G., Voorhees, P. M., Usmani, S. Z., & Sborov, D. W. (2025) · Advances in Oncology · doi:10.1016/j.yao.2025.02.002
Podar, K. (2025) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-025-01030-x
“More recent data demonstrate even higher anti-MM efficacy of CAR T cells when used in earlier lines of therapy [57, 58].”
Lal, B. M., Pandey, T., Alzubi, M., Alrawabdeh, J. A., Shaughnessy, J. D., Zhan, F., Siegel, E. R., Schinke, C., Thanendrarajan, S., Zangari, M., et al. (2025) · Bone Marrow Transplantation · doi:10.1038/s41409-025-02607-0
Bal, S., Magnusson, T., Ravi, G., Giri, S., Godby, K. N., Dhakal, B., Callander, N. S., Silbermann, R. W., Dholaria, B., Reddy, V., et al. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01252-6 · Cited by 2
“TCRT and other drug classes such as CELMoDs ™ have demonstrated outstanding depth and duration of response in relapsed MM [26 – 30].”
Self-citationČemažar, L., Škerget, M., & Skopec, B. (2025) · Medicina · doi:10.3390/medicina61050859 · Cited by 1
Neue Möglichkeiten für die Rezidivtherapie
Hentrich, M., Mertens, L., & Högner, M. (2025) · InFo Hämatologie + Onkologie · doi:10.1007/s15004-025-0954-5
Adoptive cellular therapies in multiple myeloma
Kegyes, D., Borlea, B., Damian, M., Țigu, A. B., Nistor, M., Cenariu, D., Munteanu, R. A., Gulei, D., DASCALESCU, A. S., Antohe, I., et al. (2025) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2025.101638
Self-citationResearch Progress on Drug Combination Therapy for Multiple Myeloma
Zhang, Z. (2025) · Theoretical and Natural Science · doi:10.54254/2753-8818/2025.au23421
Hirano, S., Hanada, K., & Maeda, H. (2025) · Scientific Reports · doi:10.1038/s41598-025-05053-6
Ueda, Y., Terao, T., Fujii, N., Mino, T., Kubota, S., Hayashino, K., Fujiwara, K., Kondo, T., Seike, K., Fujiwara, H., et al. (2025) · International Journal of Hematology · doi:10.1007/s12185-025-04016-x
“Despite being a clinically important complication of MM, patients with amyloidosis have been excluded from clinical trials of commercial BCMA-CAR-T cell therapies [1, 3].”
Hematological Treatments and Disease Modifying Therapies in AL Cardiac Amyloidosis
Lebel, E., Even‐Zohar, N. G., & Gatt, M. E. (2025) · Springer eBooks · doi:10.1007/978-3-031-88342-2_14
Harrer, D. C., Herrmann, M., & Hansmann, L. (2025) · Springer Reference Medizin · doi:10.1007/978-3-662-46764-0_55-1
Liu, Z., Lei, W., Liu, X., Liu, H., Ding, K., Song, J., & Fu, R. (2025) · Advanced Science · doi:10.1002/advs.202502448
Real-world data provide a CARbon copy for ide-cel
Schmidt, T. M. (2025) · Blood · doi:10.1182/blood.2025029274
Current status and challenges of CAR-T cell therapy for hematologic malignancies
Kagoya, Y. (2025) · Japanese Journal of Transplantation and Cellular Therapy · doi:10.7889/tct-25-002
Sutphin, J., LeBlanc, T. W., Janssen, E. M., Hester, L., Wallace, M. J., Johnson, F. R., & Reed, S. D. (2025) · Cancer Medicine · doi:10.1002/cam4.71072 · Cited by 1
Bashy, B., Shah, D., Steensma, D. P., Oekelen, O. V., Chakraborty, R., & Mohyuddin, G. R. (2025) · British Journal of Haematology · doi:10.1111/bjh.70042
Time-tested safety: FCARH143’s 5-year myeloma journey
Hadidi, S. A. (2025) · Blood · doi:10.1182/blood.2025029157
Ciltacabtagén autoleucel y talquetamab en mieloma múltiple
Vaca, E. R. (2025) · Panorama actual del medicamento · doi:10.63105/49.484.3
Mougiakakos, D. (2025) · Die Onkologie · doi:10.1007/s00761-025-01779-0
Huynh, T.-H., Clampitt, B. A., Chose, C., Nester, M. D., Joyce, D. M., Binitie, O. T., Freeman, C. L. L., & Lazarides, A. L. (2025) · Journal of the American Academy of Orthopaedic Surgeons · doi:10.5435/jaaos-d-25-00392 · Cited by 1
Gay, F., Marchetti, E., & Bertuglia, G. (2025) · Kompass Onkologie · doi:10.1159/000547999
Improving Clinical Decisions Through Primary Trial Data Review—The Regulatory Lens
Jiang, N., Yang, Z., & Li, N. (2025) · JAMA Oncology · doi:10.1001/jamaoncol.2025.3532
Multilevel Drivers of Disparities in Cardio-Oncology
McCrohan, M., Busby, T., Quiroga, D. M., Branch, M. E., Sutton, A. L., Brown, S.-A. N., Ganatra, S., Ghazi, S. M., Kola-Kehinde, O. O., Ferdousi, M., et al. (2025) · Oxidative stress in applied basic research and clinical practice · doi:10.1007/978-3-031-97517-2_2
Hentrich, M., & Straka, C. (2025) · Trillium Krebsmedizin · doi:10.47184/tk.2025.05.3
DaSilva, B. A., Neugut, A. I., Fojo, T., & Bates, S. E. (2025) · The Oncologist · doi:10.1093/oncolo/oyaf336
Camara-Peña, S., Rodríguez-Márquez, P., Planell, N., Calleja-Cervantes, M. E., Jordana-Urriza, L., Cinnirella, G., Reich-Zeliger, S., Rodríguez‐Otero, P., Tamariz‐Amador, L., Ochoa, I., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.11.681788
Belantamab mafodotin for the treatment of multiple myeloma
Oriol, A., Ibarra, G., Loscos, J., & Abril, L. (2025) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2025.2576502
“Immunotherapeutic agents, including chimeric antigen receptor T-cells (CAR-Ts) and T-cell engagers (TCEs), most of them targeting the B-cell maturation antigen on plasma cells, are rapidly moving from the advanced disease setting to earlier lines of therapy [5,6].”
Self-citationMonoclonal gammopathies and their management in Gaucher disease type 1
Lorber, J., & Rosenbloom, B. E. (2025) · Rare Disease and Orphan Drugs Journal · doi:10.20517/rdodj.2025.30
CAR T‐cell therapy shows impressive outcomes for patients with refractory multiple myeloma
Nierengarten, M. B. (2025) · Cancer · doi:10.1002/cncr.70057
How should we choose optimal salvage treatments following BCMA-directed CAR T-cell therapy?
Suresh, A., Pan, D., Lipof, J. J., Kumar, A. D., Arora, S., Sayre, P. H., Wolf, J. L., Martin, T. G., Chari, A., & Chung, A. (2025) · Immunotherapy · doi:10.1080/1750743x.2025.2571392 · Cited by 1
“This again may be complicated by the high rate of cyto-penias after BCMA CAR-T [1,6].”
Arias, M. S. N. (2025) · Cureus · doi:10.7759/cureus.94807 · Cited by 1
Schwiertz, V., de Jorna, R., Quintard, A., Lester, M., Pinturaud, M., Cormier, N., D’Huart, É., Fougereau, E., Carvalho, M., Sourisseau, B., et al. (2025) · Hematological Oncology · doi:10.1002/hon.70144 · Cited by 1
Luyckx, B., Derollez, M., Staessens, E., Verhee, A., Fijałkowska, D., Vlierberghe, P. V., Goossens, S., Clarisse, D., & Bosscher, K. D. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118656
Jagannath, S., Kharat, A. A., Chinaeke, E. E., Fu, A. Z., Perciavalle, M., Huo, S., & Qureshi, Z. P. (2025) · Journal of Medical Economics · doi:10.1080/13696998.2025.2583668 · Cited by 1
Mileage matters: long-distance performance of CARs in multiple myeloma
Jurgens, E. M., Usmani, S. Z., & Merz, M. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-012730
Mainou, M., Alsadhan, M., Tsapa, K., Visram, A., Mian, H. S., Popat, R., Mai, E. K., Chakraborty, R., Hadidi, S. A., Mohan, M., et al. (2025) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaf326
“35,36 These findings underscore the tension between feasibility and clinical relevance in endpoint selection.”
Self-citationCAR T-cell therapies—a road trip with CAR-Ts into the “near” future: Short review
Rudzki, J. D. (2025) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-025-01080-1
“…are now available in Europe for B-cell malignancies, and extended approvals in some indications have led them to move forward to a new front position in treatment algorithms like the National Comprehensive Cancer Center (NCCN) guidelines or European Hematology Association (EHA) standards [2, 8–14].”
Kaedbey, R., Venner, C. P., Reece, D. E., Hay, K. A., Gul, E., Su, J., McCurdy, A. B. R., Chu, M. P., Jimenez-Zepeda, V. H., Song, K., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.10.026
Medical tourism for cellular therapy: a clinical perspective
Esther, C. H. L., Fan, B. E., Hew, Y. Y., & Poon, L. M. (2025) · The Lancet Haematology · doi:10.1016/s2352-3026(25)00294-7 · Cited by 1
Neue Medikamente, neue Nebenwirkungen? – Spezielle Nebenwirkungen der CAR-T-Zelltherapie
Rörden, M., & Häring, M. (2025) · TumorDiagnostik & Therapie · doi:10.1055/a-2649-3063
Characteristics and utilization of the three BCMA-targeted therapies in multiple myeloma
Mihara, K., & Miyama, T. (2025) · International Journal of Hematology · doi:10.1007/s12185-025-04128-4
“The CRS was observed in 76.1% of patients, including 1.1% with grade 3 or higher, and ICANS occurred in 4.5% of patients without any grade 3 or higher cases [3].”
InfluentialKlomberg, K. M., Gelderloos, M., Kooistra, H. A. M., Nijland, M., de Bock, G. H., Huls, G. A., Brink, M., Roeloffzen, W. W. H., & Plattel, W. J. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.12.007
Self-citationLuong, V., Kashif, M., Uttervall, K., Bohlin, A., Öster, A., Qu, Y., Lee, S., Mendes, J., Hoorenbeeck, S. V., Franck, E. H., et al. (2025) · Clinical Hematology International · doi:10.46989/001c.146250
Biard, L., Lévy, V., Chevret, S., Künkele, A., Grunwald, S., Aiuti, A., Møller, B. K., Debets, R., Mielke, S., Eldere, J. V., et al. (2025) · Molecular Therapy Advances · doi:10.1016/j.omta.2025.201651 · Cited by 1
Kosch, R., Yousefi, B., Laubach, N. C., Truger, M. S., Haferlach, T., Gersting, S. W., Teipel, R., Sonnemann, P., Al-Bazaz, M., Artzenroth, J. C., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-8568919/v1
Alsina, M., Shah, N., Jagannath, S., Kaufman, J. L., Siegel, D. S. D., Munshi, N. C., Rosenblatt, J. M., Lin, Y., Jakubowiak, A. J., Derman, B. A., et al. (2026) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-24-0527 · Cited by 1
Tomasik, J., Shouval, R., Gafter‐Gvili, A., Topiłko, J., Bilicki, D., & Basak, G. W. (2026) · European Journal Of Haematology · doi:10.1111/ejh.70123 · Cited by 1
“The study recruited patients with one to three prior therapy lines [4].”
InfluentialLandgren, O., Abonour, R., & Kazandjian, D. G. (2025) · Seminars in Hematology · doi:10.1053/j.seminhematol.2026.01.002 · Cited by 3
Refuel and endure: improving metabolic fitness and efficacy in CAR-T therapy
Munoz, I., Beavis, P. A., Darcy, P. K., & Sek, K. (2026) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2026.101583
Sahara, N., Matsunaga, T., Chie, G., Mizusawa, M., Miura, Y., Kobayashi, S., Fujii, T., & Ohno, N. (2026) · International Journal of Hematology · doi:10.1007/s12185-026-04172-8
“…T cell therapies have demonstrated high response rates in patients with triple-class-exposed (TCE) RRMM, defined as those previously treated with at least one PI, one Imid, and one anti-CD38 mAb, and whose disease is refractory to or has relapsed after their most recent antimy-eloma regimen [3, 4].”
Ahmed, Z., Hamouche, W., Ahmad, S. O., Yu, J., Chowdhury, R. B., Gupta, S., Sullivan, D., Duffy, C., Ahmad, S., Anderson, K. C., et al. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2026.01.015 · Cited by 1
Chimeric Antigen Receptor T-Cell Therapy
Hays, P. V. (2026) · Springer eBooks · doi:10.1007/978-3-032-14437-9_9
Advances in the pathophysiology and treatment of anaemia in multiple myeloma
Giuliani, N., Palma, B. D., & Notarfranchi, L. (2026) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000911 · Cited by 1
Song, Z., Fu, Q., & Du, J. (2026) · Hematological Oncology · doi:10.1002/hon.70179 · Cited by 1
“The rates of ICANS in ide‐cel and cilta‐ cel recipients were 18%–28% and 4.5%–17% in US cohorts [17, 21, 23, 26, 36, 37], respectively.”
InfluentialYasui, H., Doki, N., Yan, W., Imai, K., & Ishida, T. (2026) · Cells · doi:10.3390/cells15040380 · Cited by 2
“Recent post hoc analyses of the phase 3 CARTITUDE-4 trial have provided the most robust evidence to date supporting the clinical relevance of effective bridging therapy [4,11].”
InfluentialSelf-citationHämatologische Neoplasien und solide Tumore
Ganser, A., Hertenstein, B., & Ludwig, W. (2026) · Springer eBooks · doi:10.1007/978-3-662-72738-6_5
Hansen, D. K., Lu, X., Puglianini, O. A. C., Zhang, E., Usmani, S. Z., Sachdev, R., Perciavalle, M., Wiest, D. D., Huo, S., Lee, S., et al. (2026) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2026.2634771 · Cited by 2
Overcoming Microenvironment-Driven Resistance to CAR-T Therapy in Multiple Myeloma
Saez, G., Khusial, R., Hamedi, K. R., Arreola, N., Khuu, H., & Kissel, H. (2026) · Lymphatics · doi:10.3390/lymphatics4010015 · Cited by 1
Pasvolsky, O., Marcoux, C., Milton, D. R., Tanner, M. R., Bashir, Q., Srour, S. A., Saini, N. Y., Lin, P., Siddiqui, U. R., Khan, H., et al. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2026.02.014
Neurologic Complications in Immuno-oncology
Primdahl, D., Linnet, T., Kim, H., Dixit, K., Miska, J. M., & Shah, S. (2026) · Advances in Oncology · doi:10.1016/j.yao.2026.01.007
When Outcomes With Bispecifics Start to Resemble CAR T Cells: Lessons From MajesTEC-3
Pan, D., Kumar, A., Lipof, J. J., Chung, A., & Chari, A. (2026) · The Hematologist · doi:10.1182/hem.v23.2.202624
Shivaraj, K., Mamlouk, O., Tchakarov, A. S., Patel, K. K., & Abudayyeh, A. (2026) · Kidney Medicine · doi:10.1016/j.xkme.2026.101326
Ciltacabtagene Autoleucel in Monoclonal Gammopathy of Renal Significance
Haddad, N. A., Hashmi, H., & Sathick, I. J. (2026) · Kidney International Case Reports · doi:10.1016/j.kintcr.2026.100009
Mina, R., Mylin, A. K., Yokoyama, H., et al. (2026) · Journal of Patient-Reported Outcomes · doi:10.1186/s41687-026-01034-z
Self-citationRamanan, S. P., Abioye, O. F., Atrash, S., Wu, J., Mudaranthakam, D. P., Mazloom, A., Alkharabsheh, O. A., Shah, M. R., Mahmoudjafari, Z., Snyder, J. A., et al. (2026) · Current Oncology · doi:10.3390/curroncol33030164
“…OS improvements with daratumumab-containing salvage triplets, and KarMMa-331 and CARTITUDE-432 demonstrated superior PFS for ide-cel and cilta-cel versus standard regimens in patients who had received prior therapy, which may delay OS divergence between upfront maintenance strategies [31,32].”
Role of Radiotherapy in the Era of Novel Immune‐Based Treatment Strategies for Multiple Myeloma
Schlusemann, T., Shumilov, E., Reinartz, G., Steike, D. R., Lohmann, S., Gravemeyer, S., Stelljes, M., Lenz, G., Eich, H. T., & Oertel, M. (2026) · Hematological Oncology · doi:10.1002/hon.70186
“T) [12, 13] for relapsed and refractory multiple myeloma (RRMM).”
InfluentialReview of advances in CAR-T therapies in malignant hematology
Amirmokhtari, N., & Lutfi, F. U. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1768614
Choosing Wisely in First Relapse of Multiple Myeloma: Expert Insights on Treatment Selection
Hadidi, S. A., Costello, C. L., Costa, L. J., Dhakal, B., Georges, P., Gajra, A., Lin, Y., Bhargava, R. S., Paner-Straseviciute, A., & Vij, R. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2026.03.009 · Cited by 1
Self-citationRöhnert, M. A., Seifert, A., Trautmann‐Grill, K., Röllig, C., Zimmer, K., Egger‐Heidrich, K., Bill, M., Heberling, L., Schulze, F., Blechschmidt, M., et al. (2026) · Transfusion · doi:10.1111/trf.70165 · Cited by 1
Ding, X., Ai, K., Wu, S., Wang, H., Zhang, H., & Li, Y. (2026) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2026.03.031
Shapiro, J., Oh, T. S., Vadasz, B., de Castro, G., Wilkey, A., Wolniak, K. L., Zhu, F., Mehta, J., Singhal, S., & Lin, A. Y. (2026) · eJHaem · doi:10.1002/jha2.70277
Phan, T. L., Hijazi, A., Xi, R., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1783051
Self-citationBAR and LAR as mortality predictors in critically ill multiple myeloma patients: a MIMIC-IV studyPreprint
Xu, H., Jiang, C., Chen, D., Lu, J., Wang, L., Chen, F., & Zhong, L. (2026) · Research Square · doi:10.21203/rs.3.rs-9224218/v1
Self-citationIn reply: Why selinexor remains a subpar option?
Mohyuddin, G. R., & Meirson, T. (2026) · The Oncologist · doi:10.1093/oncolo/oyag113
T-cell engagers in rheumatology
Nordmann-Gomes, A., Khalili, L., Wax, S. D., et al. (2026) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2026.102146
Kennedy, C. T., & Banerjee, R. K. (2026) · Therapeutic Advances in Hematology · doi:10.1177/20406207261441044
Corradini, P., Musto, P., Galeone, C., Mariani, P., Resci, F., & Cavo, M. (2026) · Leukemia Research · doi:10.1016/j.leukres.2026.108230
Self-citationTargeting integrin αvβ3 by chimeric antigen receptor neural stem cell (CAR-NSC) therapy for strokePreprint
Rust, R., Weber, R., Rentsch, N. H., Buil, B. A., Habib, P., Bodenmann, C., Zürcher, K. J., Uhr, D., Meier, D., Generali, M., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.11.717950
“This approach draws inspiration from the clinical success of chimeric antigen receptor (CAR) T-cell therapies and the broader principles of synthetic biology, where synthetic receptors are used to couple environmental recognition with tailored cellular responses 10,11 .”
Role B-cell maturation antigenu v léčbě mnohočetného myelomu
Vilímová, K., Kušnierová, P., Mihályová, J., & Hájek, R. (2026) · Klinická biochemie a metabolismus · doi:10.61568/kbm.2026.001
Bleeding and thrombosis in patients receiving chimeric antigen receptor T-cell therapy
Lee, D., Danielian, P. L. L. B., & Leader, A. (2026) · Bleeding Thrombosis and Vascular Biology · doi:10.4081/btvb.2026.461 · Cited by 1
Improving control arms in 2026 US myeloma trials
Ding, K., Kunesh, J., Neupane, K., & Mohyuddin, G. R. (2026) · Blood Advances · doi:10.1182/bloodadvances.2026020329 · Cited by 1
Metadata
- Authors
- San-Miguel, J., Dhakal, B., Yong, K., Spencer, A., Anguille, S., Mateos, M.-V., Fernández de Larrea, C., Martínez-López, J., Moreau, P., Touzeau, C., Leleu, X., Avivi, I., Cavo, M., Ishida, T., Kim, S. J., Roeloffzen, W., van de Donk, N. W. C. J., Dytfeld, D., Sidana, S., Costa, L. J., Oriol, A., Popat, R., Khan, A. M., Cohen, Y. C., Ho, P. J., Griffin, J., Lendvai, N., Lonardi, C., Slaughter, A., Schecter, J. M., Jackson, C. C., Connors, K., Li, K., Zudaire, E., Chen, D., Gilbert, J., Yeh, T.-M., Nagle, S., Florendo, E., Pacaud, L., Patel, N., Harrison, S. J., & Einsele, H.
- Affiliations
- From the Cancer Center Clínica Universidad de Navarra, Centro Investigación Medica Aplicada, Instituto de Investigación de Navarra, Centro Investigación Biomédica en Red Cáncer (CIBERONC), Pamplona (J.S.-M.), the University Hospital of Salamanca, Instituto de Investigación Biomédica de Salamanca, Centro Investigación del Cáncer, CIBERONC, Salamanca (M.-V.M.), the Amyloidosis and Myeloma Unit, Department of Hematology, Hospital Clínic of Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona (C.F.L.), the Hematological Malignancies Clinical Research Unit, Hospital 12 de Octubre Universidad Complutense, Centro Nacional de Investigaciones Oncológicas, CIBERONC, Madrid (J.M.-L.), and the Institut Català d’Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Badalona (A.O.) — all in Spain; the Medical College of Wisconsin, Milwaukee (B.D.); the University College London Cancer Institute (K.Y.) and University College London Hospitals, NHS Foundat...
- Medical College of Wisconsin (US)
- Inserm (FR)
- University Medical Center Groningen (NL)
- Poznan University of Medical Sciences (PL)
- University College London Hospitals NHS Foundation Trust (GB)
- The University of Sydney (AU)
- The Royal Melbourne Hospital (AU)
- ORCID
- Dhakal, Binod
- Yong, Kwee
- Spencer, Andrew
- Anguille, Sébastien
- Mateos, María-Victoria
- Moreau, Philippe
- Touzeau, Cyrille
- Leleu, Xavier
- Avivi, Irit
- Ishida, Tadao
- Kim, Seok Jin
- Roeloffzen, Wilfried
- Dytfeld, Dominik
- Sidana, Surbhi
- Costa, Luciano J.
- Oriol, Albert
- Popat, Rakesh
- Khan, Abdullah M.
- Ho, P. Joy
- Lendvai, Nikoletta
- Schecter, Jordan M.
- Jackson, Carolyn C.
- Li, Katherine
- Chen, Diana
- Nagle, Sarah
- Pacaud, Lida
- Patel, Nitin
- Harrison, Simon J.
- Einsele, Hermann
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-07-27
- Volume
- 389
- Issue
- 4
- Pages
- 335-347
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4379375986
- Semantic Scholar
- e537b398daa738a9f57ecb0da894878f49df8dae
- Cited by
- 827
- References
- 27
- Citations by year
- 2026: 257 · 2025: 279 · 2024: 230 · 2023: 60
- FWCI
- 169.95
- Type
- journal article
- Language
- en
- Open access
- green
- research.rug.nl
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, other-oa)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, other-oa)
- UCL Discovery (University College London) (submittedVersion)
- Minerva Access (University of Melbourne) (submittedVersion)
- Funders
- Janssen Research & Development, LLC
- Legend Biotech USA Inc.
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- cilta-cel, ciltacabtagene autoleucel, lenalidomide-refractory multiple myeloma, progression-free survival, standard of care comparison, cytokine release syndrome, neurotoxicity, non-relapse mortality, minimal residual disease, relapsed/refractory multiple myeloma, adverse events
- MeSH terms
- Antineoplastic Agents, Immunological, Lenalidomide, Progression-Free Survival, Humans, Multiple Myeloma, Immunotherapy, Adoptive, Drug Resistance, Neoplasm, Neurotoxicity Syndromes, B-Cell Maturation Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-12, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-12 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.